References
- Stern RS. The prevalence of acne on the basis of physical examination. J Am Acad Dermatol 1992; 26(6):931–5
- Webster GF. Inflammation in acne vulgaris. J Am Acad Dermatol 1995; 33(2 Pt 1):247–53
- Leyden JJ. New understandings of the pathogenesis of acne. J Am Acad Dermatol 1995; 32(5 Pt 3):15–25S
- Cargnello JA. Acne: what's new? Med J Aust 1996; 165(3):153–8
- Kaminer MS, Gilchrest BA. The many faces of acne. J Am Acad Dermatol 1995; 32(5 Pt 3):6–14S
- Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in pre-menarchal girls: an early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 1994; 130(3):308–14
- Hurwitz S. Acne vulgaris: pathogenesis and management. Pediatr Rev 1994; 15(2):47–52
- Ives TJ. Benzoyl peroxide. Am Pharm 1992; NS32(8):33–8
- Gibson JR. Rationale for the development of new topical treatments for acne vulgaris. Cutis 1996; 57(1 Suppl):13–9
- Thiboutot DM. An overview of acne and its treatment. Cutis 1996; 57(1 Suppl):8–12
- Plewig G, Kligman AM. Acne and rosacea. 2d ed. New York: Springer-Verlag, 1993:584–8
- Rothman KF, Lucky AW. Acne vulgaris. Adv Dermatol 1993; 8:347–75
- Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996; 34(3):482–5
- Plewig G, Kligman AM,” pp 599–602
- Graupe K, Cunliffe WJ, Gollnick HP, et al. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis 1996; 57(1 Suppl):20–35
- Fitton A, Goa KL. Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 1991; 41(5):780–98
- Gardner KJ, Cunliffe WJ, Eady EA, et al. Variation in comedonal antibiotic concentrations following application of topical tetracycline for acne vulgaris. Br J Dermatol 1994; 131 (5):649–54
- Oakley A Rademaker M, Duffill M, et al. Propionibacterium: resistance of acne to antibiotics. (Letter) N Z Med J 1995; 108(993):43–4
- Plewig G, Kligman AM, 11 pp 611–3
- Layton AM, Hughes BR, Hull SM, et al. Seborrhoea: an indicator for poor clinical response in acne patients treated with antibiotics. Clin Exp Dermatol 1992; 17(3):173–5
- Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant Propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol 1993; 128(5):556–60
- Eady EA, Jones CE, Tipper JL, et al. Antibiotic resistant Propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1993; 306(6877):555–6
- Driscoll MS, Rothe MJ, Abrahamian L, et al. Long-term oral antibiotics for acne: is laboratory monitoring necessary? J Am Acad Dermatol 1993; 28(4):595–602
- Murphy AA, Zacur HA, Charache P, et al. The effect of tetracycline on levels of oral contraceptives. Am J Obstet Gynecol 1991; 164(1 Pt 1):28–33
- Neely JL, Abate M, Swinker M, et al. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstet Gynecol 1991; 77(3):416–20
- Miller DM, Helms SE, Brodell RT. A practical approach to antibiotic treatment in women taking oral contraceptives. J Am Acad Dermatol 1994; 30(6):1008–11
- Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 1995; 29(7–8):736–42
- Plewig G, Kligman AM,” pp 662–9
- Plewig G, Kligman AM,” pp 625–7
- Goulden V, Layton AM, Cunliffe WJ. Current indications for isotretinoin as a treatment for acne vulgaris. Dermatology 1995; 190(4):284–7
- Harms M. Isotretinoin: 10 years on. (Editorial) Dermatology 1993; 186(2):81–2
- Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 1992; 27(6 Pt 2):2–7S
- Barth JH, Macdonald-Hull SP, Mark J, et al. Isotretinoin therapy ' for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol 1993; 129(6):704–7